2015
Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart
Bar N, Parker TL, Dhodapkar MV. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart. Journal Of Clinical Oncology 2015, 33: 3689-3690. PMID: 26371139, DOI: 10.1200/jco.2015.63.2224.Peer-Reviewed Original ResearchAmyloidosisAntineoplastic Agents, AlkylatingFemaleHematopoietic Stem Cell TransplantationHumansImmunoglobulin Light ChainsMaleMelphalanMyeloablative Agonists
2012
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant
Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntilymphocyte SerumAntineoplastic Combined Chemotherapy ProtocolsBusulfanErythemaFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedRetrospective StudiesTransplantation ConditioningVidarabineYoung AdultConceptsAllogeneic PBSC transplantCutaneous toxicityConditioning regimenPBSC transplantsToxic erythemaLow treatment-related mortalityDoses of BUEffective conditioning regimenPalms/solesTreatment-related mortalityEvaluable patientsMost patientsMedian onsetStandard dosesTransplant physiciansClinical presentationScrotal involvementSpecific therapyAllergic reactionsInappropriate treatmentRetrospective analysisHigh incidencePatientsMyeloid neoplasiaBU/